CA3036978A1 - Immune modulation with tlr9 agonists for cancer treatment - Google Patents
Immune modulation with tlr9 agonists for cancer treatment Download PDFInfo
- Publication number
- CA3036978A1 CA3036978A1 CA3036978A CA3036978A CA3036978A1 CA 3036978 A1 CA3036978 A1 CA 3036978A1 CA 3036978 A CA3036978 A CA 3036978A CA 3036978 A CA3036978 A CA 3036978A CA 3036978 A1 CA3036978 A1 CA 3036978A1
- Authority
- CA
- Canada
- Prior art keywords
- cancer
- administered
- imo
- tumor
- agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010028980 Neoplasm Diseases 0.000 claims description 133
- 239000003795 chemical substances by application Substances 0.000 claims description 54
- 229940045513 CTLA4 antagonist Drugs 0.000 claims description 43
- 238000000034 method Methods 0.000 claims description 42
- 201000011510 cancer Diseases 0.000 claims description 37
- 230000002601 intratumoral effect Effects 0.000 claims description 36
- 238000002560 therapeutic procedure Methods 0.000 claims description 32
- 238000011282 treatment Methods 0.000 claims description 30
- 229940044655 toll-like receptor 9 agonist Drugs 0.000 claims description 28
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims description 23
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims description 23
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims description 23
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 22
- 229960002621 pembrolizumab Drugs 0.000 claims description 21
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 claims description 18
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 claims description 18
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 claims description 18
- 229960003301 nivolumab Drugs 0.000 claims description 18
- 229960005386 ipilimumab Drugs 0.000 claims description 17
- 206010027480 Metastatic malignant melanoma Diseases 0.000 claims description 14
- 108091034117 Oligonucleotide Proteins 0.000 claims description 14
- 208000021039 metastatic melanoma Diseases 0.000 claims description 14
- 238000002347 injection Methods 0.000 claims description 12
- 239000007924 injection Substances 0.000 claims description 12
- 230000004044 response Effects 0.000 claims description 12
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims description 11
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims description 11
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims description 10
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims description 10
- 210000003491 skin Anatomy 0.000 claims description 8
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims description 6
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 claims description 6
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 claims description 6
- 102000017578 LAG3 Human genes 0.000 claims description 6
- 208000020816 lung neoplasm Diseases 0.000 claims description 6
- 206010009944 Colon cancer Diseases 0.000 claims description 5
- 208000037819 metastatic cancer Diseases 0.000 claims description 5
- 208000011575 metastatic malignant neoplasm Diseases 0.000 claims description 5
- 108010074708 B7-H1 Antigen Proteins 0.000 claims description 4
- 102000008096 B7-H1 Antigen Human genes 0.000 claims description 4
- 206010060862 Prostate cancer Diseases 0.000 claims description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 4
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 4
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims description 4
- 210000000481 breast Anatomy 0.000 claims description 4
- 210000001072 colon Anatomy 0.000 claims description 4
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims description 4
- 238000012423 maintenance Methods 0.000 claims description 4
- 201000001441 melanoma Diseases 0.000 claims description 4
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 4
- 210000002307 prostate Anatomy 0.000 claims description 4
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 4
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims description 3
- 230000003442 weekly effect Effects 0.000 claims description 3
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 208000002030 Merkel cell carcinoma Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 208000017763 cutaneous neuroendocrine carcinoma Diseases 0.000 claims description 2
- 230000002496 gastric effect Effects 0.000 claims description 2
- 208000005017 glioblastoma Diseases 0.000 claims description 2
- 201000010536 head and neck cancer Diseases 0.000 claims description 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 2
- 201000010982 kidney cancer Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 238000010254 subcutaneous injection Methods 0.000 claims description 2
- 206010044412 transitional cell carcinoma Diseases 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 102100023990 60S ribosomal protein L17 Human genes 0.000 claims 1
- 238000001802 infusion Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 239000007929 subcutaneous injection Substances 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 25
- 230000000259 anti-tumor effect Effects 0.000 description 24
- 210000001744 T-lymphocyte Anatomy 0.000 description 20
- 238000009169 immunotherapy Methods 0.000 description 19
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 17
- 230000000694 effects Effects 0.000 description 16
- 230000014509 gene expression Effects 0.000 description 15
- 206010027458 Metastases to lung Diseases 0.000 description 12
- 238000013461 design Methods 0.000 description 12
- 230000009885 systemic effect Effects 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 11
- 210000004443 dendritic cell Anatomy 0.000 description 10
- 238000007920 subcutaneous administration Methods 0.000 description 10
- 230000004614 tumor growth Effects 0.000 description 10
- 229940055760 yervoy Drugs 0.000 description 10
- 229940043367 IDO1 inhibitor Drugs 0.000 description 9
- 206010027476 Metastases Diseases 0.000 description 9
- 238000002648 combination therapy Methods 0.000 description 9
- 230000009401 metastasis Effects 0.000 description 9
- 238000009097 single-agent therapy Methods 0.000 description 9
- 102000002689 Toll-like receptor Human genes 0.000 description 8
- 108020000411 Toll-like receptor Proteins 0.000 description 8
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 8
- 206010061289 metastatic neoplasm Diseases 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 102100040061 Indoleamine 2,3-dioxygenase 1 Human genes 0.000 description 7
- 239000000556 agonist Substances 0.000 description 7
- 230000011664 signaling Effects 0.000 description 7
- 238000011725 BALB/c mouse Methods 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 101001037256 Homo sapiens Indoleamine 2,3-dioxygenase 1 Proteins 0.000 description 6
- 230000006023 anti-tumor response Effects 0.000 description 6
- 206010009887 colitis Diseases 0.000 description 6
- 230000003308 immunostimulating effect Effects 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 210000004072 lung Anatomy 0.000 description 6
- 208000037841 lung tumor Diseases 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 101000840545 Bacillus thuringiensis L-isoleucine-4-hydroxylase Proteins 0.000 description 5
- 208000010201 Exanthema Diseases 0.000 description 5
- 101001037255 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) Indoleamine 2,3-dioxygenase Proteins 0.000 description 5
- 239000000427 antigen Substances 0.000 description 5
- 201000005884 exanthem Diseases 0.000 description 5
- 210000002865 immune cell Anatomy 0.000 description 5
- 230000028993 immune response Effects 0.000 description 5
- 210000000987 immune system Anatomy 0.000 description 5
- 230000003902 lesion Effects 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 206010037844 rash Diseases 0.000 description 5
- 210000003289 regulatory T cell Anatomy 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 5
- 101710142585 50S ribosomal protein 6, chloroplastic Proteins 0.000 description 4
- -1 ID01 Proteins 0.000 description 4
- 230000005867 T cell response Effects 0.000 description 4
- 230000002411 adverse Effects 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 230000005975 antitumor immune response Effects 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 208000006454 hepatitis Diseases 0.000 description 4
- 231100000283 hepatitis Toxicity 0.000 description 4
- 230000008595 infiltration Effects 0.000 description 4
- 238000001764 infiltration Methods 0.000 description 4
- 230000001394 metastastic effect Effects 0.000 description 4
- 230000008685 targeting Effects 0.000 description 4
- 229950007217 tremelimumab Drugs 0.000 description 4
- YPBKTZBXSBLTDK-PKNBQFBNSA-N (3e)-3-[(3-bromo-4-fluoroanilino)-nitrosomethylidene]-4-[2-(sulfamoylamino)ethylamino]-1,2,5-oxadiazole Chemical compound NS(=O)(=O)NCCNC1=NON\C1=C(N=O)/NC1=CC=C(F)C(Br)=C1 YPBKTZBXSBLTDK-PKNBQFBNSA-N 0.000 description 3
- PFCLMNDDPTZJHQ-XLPZGREQSA-N 2-amino-7-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1h-pyrrolo[2,3-d]pyrimidin-4-one Chemical compound C1=CC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PFCLMNDDPTZJHQ-XLPZGREQSA-N 0.000 description 3
- 102000037982 Immune checkpoint proteins Human genes 0.000 description 3
- 108091008036 Immune checkpoint proteins Proteins 0.000 description 3
- 208000003251 Pruritus Diseases 0.000 description 3
- 108010060818 Toll-Like Receptor 9 Proteins 0.000 description 3
- 102100033117 Toll-like receptor 9 Human genes 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 3
- 229950006370 epacadostat Drugs 0.000 description 3
- 210000001508 eye Anatomy 0.000 description 3
- 238000002513 implantation Methods 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 210000001165 lymph node Anatomy 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 239000000902 placebo Substances 0.000 description 3
- 229940068196 placebo Drugs 0.000 description 3
- 230000037452 priming Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 108010062802 CD66 antigens Proteins 0.000 description 2
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 2
- 102100024533 Carcinoembryonic antigen-related cell adhesion molecule 1 Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 2
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 2
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 description 2
- 206010062767 Hypophysitis Diseases 0.000 description 2
- 102100040062 Indoleamine 2,3-dioxygenase 2 Human genes 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- 206010035742 Pneumonitis Diseases 0.000 description 2
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 2
- 208000025747 Rheumatic disease Diseases 0.000 description 2
- 206010040914 Skin reaction Diseases 0.000 description 2
- 230000006044 T cell activation Effects 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 210000000612 antigen-presenting cell Anatomy 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000011278 co-treatment Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- CTMZLDSMFCVUNX-VMIOUTBZSA-N cytidylyl-(3'->5')-guanosine Chemical group O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=C(C(N=C(N)N3)=O)N=C2)O)[C@@H](CO)O1 CTMZLDSMFCVUNX-VMIOUTBZSA-N 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000004041 dendritic cell maturation Effects 0.000 description 2
- 210000003162 effector t lymphocyte Anatomy 0.000 description 2
- 210000000750 endocrine system Anatomy 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 230000009036 growth inhibition Effects 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 229940126546 immune checkpoint molecule Drugs 0.000 description 2
- 230000006058 immune tolerance Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000015788 innate immune response Effects 0.000 description 2
- 230000007803 itching Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 208000011645 metastatic carcinoma Diseases 0.000 description 2
- 210000004985 myeloid-derived suppressor cell Anatomy 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 239000002777 nucleoside Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 210000001428 peripheral nervous system Anatomy 0.000 description 2
- 150000004713 phosphodiesters Chemical class 0.000 description 2
- 238000009258 post-therapy Methods 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 230000004043 responsiveness Effects 0.000 description 2
- 208000011581 secondary neoplasm Diseases 0.000 description 2
- 231100000046 skin rash Toxicity 0.000 description 2
- 231100000430 skin reaction Toxicity 0.000 description 2
- 230000035483 skin reaction Effects 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 210000004981 tumor-associated macrophage Anatomy 0.000 description 2
- YPFDHNVEDLHUCE-UHFFFAOYSA-N 1,3-propanediol Substances OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 description 1
- WERYXYBDKMZEQL-UHFFFAOYSA-N 1,4-butanediol Substances OCCCCO WERYXYBDKMZEQL-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010000097 Abdominal tenderness Diseases 0.000 description 1
- 208000003950 B-cell lymphoma Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108020000946 Bacterial DNA Proteins 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000003164 Diplopia Diseases 0.000 description 1
- 208000001382 Experimental Melanoma Diseases 0.000 description 1
- 206010015958 Eye pain Diseases 0.000 description 1
- 206010016326 Feeling cold Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 102000006354 HLA-DR Antigens Human genes 0.000 description 1
- 108010058597 HLA-DR Antigens Proteins 0.000 description 1
- 206010066476 Haematological malignancy Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 101001037261 Homo sapiens Indoleamine 2,3-dioxygenase 2 Proteins 0.000 description 1
- 101000763579 Homo sapiens Toll-like receptor 1 Proteins 0.000 description 1
- 101710120843 Indoleamine 2,3-dioxygenase 1 Proteins 0.000 description 1
- 101710120841 Indoleamine 2,3-dioxygenase 2 Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 206010025102 Lung infiltration Diseases 0.000 description 1
- 210000004322 M2 macrophage Anatomy 0.000 description 1
- 108091054437 MHC class I family Proteins 0.000 description 1
- 102000043129 MHC class I family Human genes 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 101100481579 Mus musculus Tlr11 gene Proteins 0.000 description 1
- 101100481580 Mus musculus Tlr12 gene Proteins 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 108091081548 Palindromic sequence Proteins 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 102100027010 Toll-like receptor 1 Human genes 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 206010064390 Tumour invasion Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000033289 adaptive immune response Effects 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000005809 anti-tumor immunity Effects 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 229960003852 atezolizumab Drugs 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000002619 cancer immunotherapy Methods 0.000 description 1
- 230000009400 cancer invasion Effects 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 210000003690 classically activated macrophage Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 208000029444 double vision Diseases 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000008004 immune attack Effects 0.000 description 1
- 230000005746 immune checkpoint blockade Effects 0.000 description 1
- 230000008629 immune suppression Effects 0.000 description 1
- 230000006028 immune-suppresssive effect Effects 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 230000006054 immunological memory Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 210000001365 lymphatic vessel Anatomy 0.000 description 1
- 239000003287 lymphocyte surface marker Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- DAZSWUUAFHBCGE-KRWDZBQOSA-N n-[(2s)-3-methyl-1-oxo-1-pyrrolidin-1-ylbutan-2-yl]-3-phenylpropanamide Chemical compound N([C@@H](C(C)C)C(=O)N1CCCC1)C(=O)CCC1=CC=CC=C1 DAZSWUUAFHBCGE-KRWDZBQOSA-N 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 229950010773 pidilizumab Drugs 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 210000003635 pituitary gland Anatomy 0.000 description 1
- 210000005134 plasmacytoid dendritic cell Anatomy 0.000 description 1
- 229920000166 polytrimethylene carbonate Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001902 propagating effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000001235 sensitizing effect Effects 0.000 description 1
- 230000005808 skin problem Effects 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 206010042772 syncope Diseases 0.000 description 1
- 229940066453 tecentriq Drugs 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 230000001173 tumoral effect Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 238000004383 yellowing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662394845P | 2016-09-15 | 2016-09-15 | |
| US62/394,845 | 2016-09-15 | ||
| US201762486738P | 2017-04-18 | 2017-04-18 | |
| US62/486,738 | 2017-04-18 | ||
| PCT/US2017/051742 WO2018053242A1 (en) | 2016-09-15 | 2017-09-15 | Immune modulation with tlr9 agonists for cancer treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3036978A1 true CA3036978A1 (en) | 2018-03-22 |
Family
ID=61620152
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3036978A Pending CA3036978A1 (en) | 2016-09-15 | 2017-09-15 | Immune modulation with tlr9 agonists for cancer treatment |
Country Status (10)
| Country | Link |
|---|---|
| US (6) | US10463686B2 (OSRAM) |
| EP (1) | EP3512499A4 (OSRAM) |
| JP (2) | JP7200093B2 (OSRAM) |
| KR (1) | KR20190096936A (OSRAM) |
| CN (1) | CN110114057A (OSRAM) |
| AU (1) | AU2017325981A1 (OSRAM) |
| CA (1) | CA3036978A1 (OSRAM) |
| IL (2) | IL292658A (OSRAM) |
| MX (1) | MX2019002925A (OSRAM) |
| WO (1) | WO2018053242A1 (OSRAM) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20160042917A (ko) | 2013-07-25 | 2016-04-20 | 엑시큐어, 인크. | 예방 및 치료 용도를 위한 면역자극제로서의 구형 핵산-기재 구축물 |
| US11364304B2 (en) | 2016-08-25 | 2022-06-21 | Northwestern University | Crosslinked micellar spherical nucleic acids |
| KR20190096936A (ko) | 2016-09-15 | 2019-08-20 | 이데라 파마슈티칼즈, 인코포레이티드 | 암 치료를 위하여 tlr9 작용제를 사용한 면역 조정 |
| WO2018071500A1 (en) | 2016-10-11 | 2018-04-19 | Agenus Inc. | Anti-lag-3 antibodies and methods of use thereof |
| TW202402800A (zh) | 2017-05-01 | 2024-01-16 | 美商艾吉納斯公司 | 抗ｔｉｇｉｔ抗體類和使用彼等之方法 |
| WO2018209270A1 (en) | 2017-05-11 | 2018-11-15 | Northwestern University | Adoptive cell therapy using spherical nucleic acids (snas) |
| KR20230053001A (ko) | 2017-05-19 | 2023-04-20 | 우시 바이올로직스 (상하이) 컴퍼니 리미티드 | 세포독성 t-림프구-관련 단백질 4 (ctla-4)에 대한 신규의 단일클론 항체 |
| US20210340544A1 (en) * | 2018-10-18 | 2021-11-04 | Idera Pharmaceuticals, Inc. | Tlr9 modulators for treating cancer |
| WO2020089531A1 (en) * | 2018-11-01 | 2020-05-07 | Faron Pharmaceuticals Oy | Tlr9 agonists for use in downregulating clever-1 expression on alternatively activated macrophages |
| CN113490688B (zh) | 2018-12-26 | 2025-07-29 | 希望之城公司 | 可活化的被掩蔽的抗ctla4结合蛋白质 |
| AU2021236055A1 (en) * | 2020-03-09 | 2022-10-20 | Dynavax Technologies Corporation | Active booster immunization against tetanus, diphtheria and pertussis |
| AU2021347690A1 (en) * | 2020-09-22 | 2023-05-11 | Trisalus Life Sciences, Inc. | Cancer therapy using toll-like receptor agonists |
| TW202304965A (zh) | 2021-05-04 | 2023-02-01 | 美商艾吉納斯公司 | 抗ｔｉｇｉｔ抗體、抗ｃｄ９６抗體及其使用方法 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60017259T2 (de) | 1999-08-13 | 2005-12-08 | Hybridon, Inc., Cambridge | Modulation der CPG-Oligonukleotid-vermittelten Immunstimulation durch Positionsbedingte Modifikation von Nukleosiden |
| US20040214783A1 (en) | 2002-05-08 | 2004-10-28 | Terman David S. | Compositions and methods for treatment of neoplastic disease |
| US20030129251A1 (en) | 2000-03-10 | 2003-07-10 | Gary Van Nest | Biodegradable immunomodulatory formulations and methods for use thereof |
| US20030049266A1 (en) | 2000-12-27 | 2003-03-13 | Fearon Karen L. | Immunomodulatory polynucleotides and methods of using the same |
| US7276489B2 (en) | 2002-10-24 | 2007-10-02 | Idera Pharmaceuticals, Inc. | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends |
| SI1575977T1 (sl) * | 2002-12-23 | 2010-01-29 | Dynavax Tech Corp | Imunostimulirni sekvenčni polinukleotidi in postopki za njihovo uporabo |
| US8158768B2 (en) | 2002-12-23 | 2012-04-17 | Dynavax Technologies Corporation | Immunostimulatory sequence oligonucleotides and methods of using the same |
| EP1631576A4 (en) | 2003-06-11 | 2010-08-25 | Idera Pharmaceuticals Inc | STABILIZED IMMUNOMODULATION OLIGONUCLEOTIDES |
| AU2004259204B2 (en) | 2003-07-15 | 2010-08-19 | Idera Pharmaceuticals, Inc. | Synergistic stimulation of the immune system using immunostimulatory oligonucleotides and/or immunomer compounds in conjunction with cytokines and/or chemotherapeutic agents or radiation therapy |
| CN100482673C (zh) | 2003-07-15 | 2009-04-29 | 艾德拉药物股份有限公司 | 使用免疫刺激性寡核苷酸和/或免疫子化合物结合细胞因子和/或化疗剂或放射治疗对免疫系统的协同刺激作用 |
| US7498425B2 (en) | 2004-06-15 | 2009-03-03 | Idera Pharmaceuticals, Inc. | Immunostimulatory oligonucleotide multimers |
| HRP20070012A2 (hr) | 2004-06-15 | 2007-10-31 | Idera Pharmaceuticals | Imunostimulatorski oligonukleotidni multimeri |
| KR20080030656A (ko) | 2005-07-07 | 2008-04-04 | 콜레이 파마시티컬 그룹, 인코포레이티드 | 암 치료를 위한 항-ＣＴＬＡ-4 항체 및 ＣｐＧ-모티프-함유합성 올리고데옥시뉴클레오티드의 조합 요법 |
| ATE539765T1 (de) | 2005-11-04 | 2012-01-15 | Novartis Vaccines & Diagnostic | Grippeimpfstoffe mit kombinationen aus teilchenförmigen adjuvantien und immunverstärkern |
| US7470674B2 (en) | 2005-11-07 | 2008-12-30 | Idera Pharmaceuticals, Inc. | Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides |
| US7786089B2 (en) | 2005-12-20 | 2010-08-31 | Idera Pharmaceuticals, Inc. | Immunostimulatory activity of immune modulatory oligonucleotides (IMO™) containing different lengths of palindromic segments |
| US20080031887A1 (en) | 2006-06-30 | 2008-02-07 | Joseph Lustgarten | Conjugates for inducing targeted immune responses and methods of making and using same |
| CN101610671A (zh) | 2006-12-12 | 2009-12-23 | 艾德拉药物股份有限公司 | 合成的tlr9激动剂 |
| EP2173912A4 (en) | 2007-08-01 | 2013-03-20 | Idera Pharmaceuticals Inc | NEW SYNTHETIC AGONISTS OF TLR9 |
| MX2011008067A (es) | 2009-01-30 | 2011-08-17 | Idera Pharmaceuticals Inc | Novedosos agonistas sinteticos del receptor 9 tipo toll. |
| US20130142815A1 (en) | 2010-02-09 | 2013-06-06 | Georiga Health Sciences Univ. Research Inst., Inc. | Alpha-methyl-tryptophan as an inhibitor of indoleamine dioxygenase |
| KR102017898B1 (ko) | 2010-05-14 | 2019-09-04 | 더 제너럴 하스피톨 코포레이션 | 종양 특이적 신생항원을 확인하는 조성물 및 방법 |
| FR2975600B1 (fr) * | 2011-05-24 | 2013-07-05 | Assist Publ Hopitaux De Paris | Agents pour le traitement de tumeurs |
| CN103957939A (zh) * | 2011-09-19 | 2014-07-30 | 约翰霍普金斯大学 | 癌症免疫治疗 |
| WO2014047085A2 (en) | 2012-09-20 | 2014-03-27 | Rongfu Wang | Prostate-specific tumor antigen and uses thereof |
| AU2014339816B2 (en) | 2013-10-25 | 2020-05-28 | Pharmacyclics Llc | Treatment using Bruton's tyrosine kinase inhibitors and immunotherapy |
| JP2016540042A (ja) | 2013-11-05 | 2016-12-22 | コグネート バイオサービシズ， インコーポレイテッド | がんを処置するためのチェックポイント阻害剤および治療薬の組合せ |
| WO2016030863A1 (en) | 2014-08-29 | 2016-03-03 | Glaxosmithkline Intellectual Property Development Limited | Compounds and methods for treating viral infections |
| KR20170072244A (ko) * | 2014-10-10 | 2017-06-26 | 이데라 파마슈티칼즈, 인코포레이티드 | 관문 억제제를 가지는 tlr9 효능제를 이용한 암 치료 |
| CN107949397A (zh) * | 2015-02-13 | 2018-04-20 | 特兰斯吉恩股份有限公司 | 免疫治疗疫苗和抗体组合治疗 |
| WO2016196173A1 (en) | 2015-05-29 | 2016-12-08 | Merck Sharp & Dohme Corp. | Combination of a pd-1 antagonist and cpg-c type oligonucleotide for treating cancer |
| WO2016196062A1 (en) | 2015-05-29 | 2016-12-08 | Dynavax Technologies Corporation | Intrapulmonary administration of polynucleotide toll-like receptor 9 agonists for treating cancer of the lung |
| KR20190096936A (ko) | 2016-09-15 | 2019-08-20 | 이데라 파마슈티칼즈, 인코포레이티드 | 암 치료를 위하여 tlr9 작용제를 사용한 면역 조정 |
-
2017
- 2017-09-15 KR KR1020197010562A patent/KR20190096936A/ko not_active Ceased
- 2017-09-15 US US15/705,631 patent/US10463686B2/en not_active Expired - Fee Related
- 2017-09-15 EP EP17851589.6A patent/EP3512499A4/en not_active Withdrawn
- 2017-09-15 CN CN201780067972.4A patent/CN110114057A/zh active Pending
- 2017-09-15 AU AU2017325981A patent/AU2017325981A1/en not_active Abandoned
- 2017-09-15 WO PCT/US2017/051742 patent/WO2018053242A1/en not_active Ceased
- 2017-09-15 JP JP2019514720A patent/JP7200093B2/ja active Active
- 2017-09-15 CA CA3036978A patent/CA3036978A1/en active Pending
- 2017-09-15 IL IL292658A patent/IL292658A/en unknown
- 2017-09-15 MX MX2019002925A patent/MX2019002925A/es unknown
-
2019
- 2019-03-14 IL IL265370A patent/IL265370B/en unknown
- 2019-08-30 US US16/557,597 patent/US10835550B2/en not_active Expired - Fee Related
- 2019-08-30 US US16/557,630 patent/US10772907B2/en not_active Expired - Fee Related
-
2020
- 2020-09-14 US US17/020,355 patent/US20210052625A1/en not_active Abandoned
- 2020-10-21 US US17/076,677 patent/US11224611B2/en active Active
-
2021
- 2021-10-18 JP JP2021170043A patent/JP2022009200A/ja active Pending
- 2021-12-06 US US17/543,341 patent/US20220088054A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US10835550B2 (en) | 2020-11-17 |
| US20200054663A1 (en) | 2020-02-20 |
| US10772907B2 (en) | 2020-09-15 |
| EP3512499A4 (en) | 2020-08-05 |
| JP2019529415A (ja) | 2019-10-17 |
| US10463686B2 (en) | 2019-11-05 |
| IL265370B (en) | 2022-06-01 |
| AU2017325981A1 (en) | 2019-04-11 |
| US20210052625A1 (en) | 2021-02-25 |
| US20210038630A1 (en) | 2021-02-11 |
| WO2018053242A1 (en) | 2018-03-22 |
| US20180125877A1 (en) | 2018-05-10 |
| MX2019002925A (es) | 2019-09-05 |
| IL265370A (en) | 2019-05-30 |
| KR20190096936A (ko) | 2019-08-20 |
| US20220088054A1 (en) | 2022-03-24 |
| US20200138848A1 (en) | 2020-05-07 |
| JP2022009200A (ja) | 2022-01-14 |
| US11224611B2 (en) | 2022-01-18 |
| CN110114057A (zh) | 2019-08-09 |
| EP3512499A1 (en) | 2019-07-24 |
| IL292658A (en) | 2022-07-01 |
| JP7200093B2 (ja) | 2023-01-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11224611B2 (en) | Immune modulation with TLR9 agonists for cancer treatment | |
| US20230374503A1 (en) | Combination | |
| CN104812244B (zh) | 增强癌症治疗中特异性免疫疗法的方法 | |
| Yang et al. | PD-L1: PD-1 interaction contributes to the functional suppression of T-cell responses to human uveal melanoma cells in vitro | |
| WO2022166909A1 (en) | Use of ppar-delta inhibitor in combination with immunotherapeutic drug for preparing anti-tumor drug | |
| US20230256066A1 (en) | Pharmaceutical composition for use in the treatment of cancer | |
| Dovedi et al. | Emerging targeted therapies for bladder cancer: a disease waiting for a drug | |
| JP2023505303A (ja) | 癌治療におけるｉｌ－１５及びｃｄ４０アゴニストの組合せ免疫療法 | |
| Lampson | Brain tumor immunotherapy: seeing the brain in the body | |
| AU2022201046A1 (en) | TLR9 modulators for treating cancer | |
| US20210340544A1 (en) | Tlr9 modulators for treating cancer | |
| 益田昌吾 | Inhibition of PTPN3 Expressed in Activated Lymphocytes Enhances the Antitumor Effects of Anti-PD-1 Therapy in Head and Neck Cancer, Especially in Hypoxic Environments | |
| CA3148401A1 (en) | Tlr9 modulators for treating cancer | |
| HK40058967A (en) | Tlr9 modulators for treating cancer | |
| Sun et al. | Active hexose conelated compound enhances tumor surveillance through regulating both innate and adaptive immune responses | |
| HK1259650A1 (en) | Improved interferon therapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220914 |
|
| EEER | Examination request |
Effective date: 20220914 |
|
| EEER | Examination request |
Effective date: 20220914 |
|
| EEER | Examination request |
Effective date: 20220914 |